SEI Investments
RNAC icon

SEI Investments’s Cartesian Therapeutics RNAC Stock Holding History

SEI Investments’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133K Hold
12,764
– – ﹤0.01% 3138
2026
Q1 		$78.5K Buy
+12,764
New +$90.9K ﹤0.01% 3132
2019
Q2 		– Sell
-1
Closed – – 2697
2019
Q1 		$0 Buy
+1
New +$63 ﹤0.01% 2965

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SEI Investments's RNAC Position: Q2 2026 in Review

SEI Investments held its Cartesian Therapeutics (RNAC) position steady in Q2 2026 at 12,764 shares worth $133K. The position accounts for ﹤0.01% of the portfolio, ranked #3138.

SEI Investments first reported a position in RNAC in Q1 2019 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • SEI Investments held 12,764 shares of Cartesian Therapeutics worth $133K as of Q2 2026.
  • SEI Investments left its Cartesian Therapeutics share count unchanged in Q2 2026.
  • Cartesian Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3138 holding.
  • SEI Investments first reported a position in Cartesian Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.